Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
22
|
| pubmed:dateCreated |
1976-8-2
|
| pubmed:abstractText |
In chronic active hepatitis (CAH, n=58) 70% of the HBsAg negative and 48% of the HBsAg positive cases showed a CMI against human liver specific proteins (HLPI). Using HBsAg as antigen only 12% of the HBsAg negative and 24% of the HBsAg positive cases gave a CMI response. On the basis of HBsAg and autoantibodies in the serum CAH patients could be divided into 4 subgroups. A close correlation between CMI against HLPI, sex, ANA and HL-A-8 could be detected. In a follow-up study of patients with acute virus B hepatitis (n=62) CMI against HBsAg was detected in 60% of the cases in the acute phase of the disease but in 15% only 3-6 months after the onset of the illness (n=40). In patients who developed a chronic HBsAg carrier status 3 of 5 cases remained persistently positive with HLPI as antigen in the migration inhibition test. - In non-hepatic diseases in which immunological abnormalities may be present (malignant diseases n=46, diabetes mellitus n=27, active tuberculosis, n=18 and untreated systemic lupus erythematodes, n=5) only 26% of patients with malignant diseases showed a migration inhibition with HLPI. - Using different antigens such as human liver specific proteins (HLP), rabbit liver specific proteins (RLP), brucella suis antigen and tuberculin it was possible to demonstrate the validity of the two-step migration inhibition test to detect CMI. The results with different antigens in hepatic and non-hepatic diseases demonstrated that cell-mediated immunity of HLPI is an organ specific immune reaction which is associated with acute and chronic active liver diseases as a time limited or long-lasting phenomenon. Positive reactions in some tumor patients suggest that different mechanisms may elicit an autoimmune reaction against liver antigens.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0023-2173
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
53
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1061-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1083922-Antibodies,
pubmed-meshheading:1083922-Antibodies, Antinuclear,
pubmed-meshheading:1083922-Antibody Specificity,
pubmed-meshheading:1083922-Antigen-Antibody Reactions,
pubmed-meshheading:1083922-Autoantibodies,
pubmed-meshheading:1083922-Cell Migration Inhibition,
pubmed-meshheading:1083922-Chronic Disease,
pubmed-meshheading:1083922-Diabetes Mellitus,
pubmed-meshheading:1083922-Hepatitis,
pubmed-meshheading:1083922-Hepatitis A,
pubmed-meshheading:1083922-Hepatitis B Antigens,
pubmed-meshheading:1083922-Humans,
pubmed-meshheading:1083922-Immunity, Cellular,
pubmed-meshheading:1083922-Leukocytes,
pubmed-meshheading:1083922-Liver Diseases,
pubmed-meshheading:1083922-Muscle, Smooth,
pubmed-meshheading:1083922-Neoplasms,
pubmed-meshheading:1083922-Sex Factors,
pubmed-meshheading:1083922-Tuberculosis,
pubmed-meshheading:1083922-Virus Diseases
|
| pubmed:year |
1975
|
| pubmed:articleTitle |
Organ-specificity and diagnostic value of cell-mediated immunity against a liver-specific membrane protein: studies in hepatic and non-hepatic diseases.
|
| pubmed:publicationType |
Journal Article
|